Literature DB >> 20808298

Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial.

Christine Cole Johnson1, Richard B Hayes, Robert E Schoen, Marc J Gunter, Wen-Yi Huang.   

Abstract

OBJECTIVES: Non-steroidal anti-inflammatory drugs (NSAIDs) have been documented in animal and human studies to reduce risk for colorectal cancer and adenomatous polyps, but risk modification for subgroups of the population and effects on hyperplastic polyps have been less studied.
METHODS: Data on recent use of two frequently ingested NSAIDs, aspirin and ibuprofen, were collected at baseline from participants aged 55-74 years in the 10 centers of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). Participants randomized to the intervention arm of the trial received a flexible sigmoidoscopy during a baseline examination. Follow-up of detected polyps was accomplished outside the Trial setting and relevant records were sought and abstracted. Cases (n=4,017) included subjects with a biopsy-proven polyp in the left side of the colon (descending colon, sigmoid, and rectum) detected as a consequence of PLCO screening; controls (n=38,396) were subjects with no left-sided colon polyp.
RESULTS: Regular use of aspirin (≥ 4 times/month) in the past year was inversely associated with hyperplastic polyps (odds ratios (OR)=0.8, 95% confidence interval (CI)=0.7-0.9), adenomatous polyps (OR=0.8, 95% CI=0.8-0.9), and advanced adenomas (OR=0.8, 95% CI=0.7-0.9). As frequency of aspirin use increased, the prevalence of polyps decreased significantly for each histological classification (P for trend ≤ 0.0004). Similar patterns were found for adenomas and ibuprofen. Overall protection was consistent in both the descending colon or sigmoid and the rectum, but more evident in males. In males, the OR for heavy use of combined aspirin and ibuprofen (≥ 2 times/day) was 0.6 (95% CI=0.5-0.8), as opposed to 0.9 (95% CI=0.8-1.1) in females. The protective effects of NSAIDs for females were apparent only among those with body mass index (BMI) <25 (OR=0.8, 95% CI=0.7-1.0 for regular use of NSAIDs; P interaction=0.04). We also found a slightly stronger protection of NSAIDs in the 70-74 years age group compared with those aged 55-69 years.
CONCLUSIONS: This study of a large general risk population supports previous work that recent use of aspirin and ibuprofen is associated with a decreased risk of colorectal adenomas and demonstrates that this protective effect may be stronger in certain population subgroups and is also evident for aspirin and hyperplastic polyps.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20808298      PMCID: PMC5557093          DOI: 10.1038/ajg.2010.349

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  67 in total

1.  Chemoprevention for colorectal cancer: some progress but a long way to go.

Authors:  Peter Lance
Journal:  Gastroenterology       Date:  2008-01       Impact factor: 22.682

2.  Commentary: aspirin and cancer prevention.

Authors:  Gabriel Kune
Journal:  Int J Epidemiol       Date:  2007-10-05       Impact factor: 7.196

Review 3.  Nonsteroidal anti-inflammatory drugs and cancer prevention.

Authors:  J A Baron; R S Sandler
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

4.  A randomized trial of aspirin to prevent colorectal adenomas.

Authors:  John A Baron; Bernard F Cole; Robert S Sandler; Robert W Haile; Dennis Ahnen; Robert Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Michael Beach; Gerald J Beck; John H Bond; Tim Byers; E Robert Greenberg; Jack S Mandel; Norman Marcon; Leila A Mott; Loretta Pearson; Fred Saibil; Rosalind U van Stolk
Journal:  N Engl J Med       Date:  2003-03-06       Impact factor: 91.245

5.  Hormone replacement therapy, reproductive history, and colorectal adenomas: data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (United States).

Authors:  Mark P Purdue; Pamela J Mink; Patricia Hartge; Wen-Yi Huang; Saundra Buys; Richard B Hayes
Journal:  Cancer Causes Control       Date:  2005-10       Impact factor: 2.506

6.  Chemopreventive effect of nonsteroidal anti-inflammatory drugs on the development of a new colorectal polyp or adenoma in a high-risk population: a meta-analysis.

Authors:  Emine Arzu Kanik; Hakan Canbaz; Tahsin Colak; Suha Aydin
Journal:  Curr Ther Res Clin Exp       Date:  2004-07

Review 7.  Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.

Authors:  Alaa Rostom; Catherine Dubé; Gabriela Lewin; Alexander Tsertsvadze; Nicholas Barrowman; Catherine Code; Margaret Sampson; David Moher
Journal:  Ann Intern Med       Date:  2007-03-06       Impact factor: 25.391

Review 8.  Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review).

Authors:  Randall E Harris; Joanne Beebe-Donk; Hani Doss; Deborah Burr Doss
Journal:  Oncol Rep       Date:  2005-04       Impact factor: 3.906

9.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

10.  Recruitment in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: the first phase of recruitment at Henry Ford Health System.

Authors:  Lois E Lamerato; Pamela M Marcus; Gordon Jacobsen; Christine Cole Johnson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04       Impact factor: 4.254

View more
  20 in total

1.  Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo.

Authors:  T Nie; C C Wong; N Alston; P Aro; P P Constantinides; B Rigas
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Cancer: do aspirin and other NSAIDs protect against colorectal cancer?

Authors:  Sarah Kraus; Nadir Arber
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-01-18       Impact factor: 46.802

3.  Influence of Smoking, Body Mass Index, and Other Factors on the Preventive Effect of Nonsteroidal Anti-Inflammatory Drugs on Colorectal Cancer Risk.

Authors:  Xiaoliang Wang; Andrew T Chan; Martha L Slattery; Jenny Chang-Claude; John D Potter; Steven Gallinger; Bette Caan; Johanna W Lampe; Polly A Newcomb; Niha Zubair; Li Hsu; Robert E Schoen; Michael Hoffmeister; Hermann Brenner; Loic Le Marchand; Ulrike Peters; Emily White
Journal:  Cancer Res       Date:  2018-06-19       Impact factor: 12.701

Review 4.  Aspirin for the prevention of colorectal cancer.

Authors:  X Garcia-Albeniz; A T Chan
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-08       Impact factor: 3.043

Review 5.  Aspirin in the chemoprevention of colorectal neoplasia: an overview.

Authors:  Andrew T Chan; Nadir Arber; John Burn; Whay Kuang Chia; Peter Elwood; Mark A Hull; Richard F Logan; Peter M Rothwell; Karsten Schrör; John A Baron
Journal:  Cancer Prev Res (Phila)       Date:  2011-11-14

6.  Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory injury and mitogenic stimulation.

Authors:  Marta Bombardo; Ermanno Malagola; Rong Chen; Alina Rudnicka; Rolf Graf; Sabrina Sonda
Journal:  Br J Pharmacol       Date:  2017-06-16       Impact factor: 8.739

Review 7.  Potential roles of longan flower and seed extracts for anti-cancer.

Authors:  Chih-Cheng Lin; Yuan-Chiang Chung; Chih-Ping Hsu
Journal:  World J Exp Med       Date:  2012-08-20

8.  Use of glucosamine and chondroitin supplements and risk of colorectal cancer.

Authors:  E D Kantor; J W Lampe; U Peters; D D Shen; T L Vaughan; E White
Journal:  Cancer Causes Control       Date:  2013-03-26       Impact factor: 2.506

9.  AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.

Authors:  Ying-En Lee; Hong-Lin He; Sung-Wei Lee; Tzu-Ju Chen; Kwang-Yu Chang; Chung-Hsi Hsing; Chien-Feng Li
Journal:  Tumour Biol       Date:  2014-05-16

10.  E series prostaglandins alter the proliferative, apoptotic and migratory properties of T98G human glioma cells in vitro.

Authors:  Renata N Gomes; Alison Colquhoun
Journal:  Lipids Health Dis       Date:  2012-12-11       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.